Search Results
MC# 21-39
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Retifanlimab and Epacadostat
MC# 19-25
A Phase Ib Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects with Previously Treated Advanced HER2-positive Solid Tumors
MC# 21-10
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as a Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
MC# 22-07
A Phase I, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors
MC# 22-33
Phase I/II Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors
MC# 22-01
A Phase I, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors
MC# 22-26
A Phase I/II Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
MC# 23-06
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
MC# 20-41
A Phase Ia/Ib Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
MC# 22-03
A Phase I First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors
MC# 22-42
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase I Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
